Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200356 | 1.00 | CASP1 (0.43) | CASP1MTNR1AMTNR1BALDH1A1CYP3A4 | |
| SCHEMBL6200359 | 1.00 | CASP1 (0.43) | CASP1MTNR1AMTNR1BALDH1A1CYP3A4 | |
| SCHEMBL6196793 | 0.86 | ESR2 (0.40) | CASP1CYP3A4MAPK1CA1CA2 | |
| SCHEMBL6196789 | 0.86 | ESR2 (0.40) | CASP1CYP3A4MAPK1CA1CA2 | |
| SCHEMBL6196790 | 0.86 | ESR2 (0.40) | CASP1CYP3A4MAPK1CA1CA2 | |
| SCHEMBL4623734 | 0.84 | SIRT1 (0.46) | MTNR1AMTNR1BALDH1A1CYP3A4THRB | |
| SCHEMBL6197391 | 0.84 | ALOX15 (0.42) | MTNR1AMTNR1BALDH1A1DPP4NQO2 | |
| SCHEMBL6197384 | 0.84 | ALOX15 (0.42) | MTNR1AMTNR1BALDH1A1DPP4NQO2 | |
| SCHEMBL6197387 | 0.84 | ALOX15 (0.42) | MTNR1AMTNR1BALDH1A1DPP4NQO2 | |
| SCHEMBL6243498 | 0.81 | MTNR1A (0.43) | MTNR1AMTNR1BALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1392317-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1229913-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6514965-B1 | For treating bacterial infections | ANTEX PHARMA INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1229913-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001035964-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BAK1, BAD, BAX | CASP1 8/4885MTNR1A 2087/4885MTNR1B 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.